Skip to main content

News Archive

News Archive - Susanne Clara Bard

Career Anatomy – Alec Guerra

March 31, 2025

After discovering a love of anatomy in high school, Alec Guerra was inspired to become a doctor. Through his CADRE internship in the lab of Sara Gianella, MD, he participated in several autopsies as part of ongoing research investigating how HIV persists in tissues throughout the human body.

The Language of Numbers - Luna Glenn Reyes

March 31, 2025

Luna Glenn Reyes has always excelled at math. As a CADRE intern in the lab of Lindsey Burnett, M.D., Ph.D., she used the tools of biostatistics to investigate women’s pelvic floor disorders.

No Shortage of Solutions

February 7, 2025

Pharmacists at UC San Diego are working hard to help with the nationwide drug shortage crisis.

How Healthy Stem Cells Turn Into Oral Cancer

February 4, 2025

UC San Diego researchers have identified the molecular and cellular mechanisms that transform healthy stem cells into oral cancer at the earliest stages of the disease.

Enzyme Promoting Tumor Growth and Spread in Pancreatic Cancer Identified

January 2, 2025

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study by UC San Diego School of Medicine researchers.

Staphylococcus Aureus Thwarts Vaccines by Turning on a Protein That Halts Immune Response

December 16, 2024

After dozens of clinical trials, there are still no effective vaccines against Staphylococcus aureus. In two new studies, scientists report that the pathogen turns on the protein interleukin 10, shutting down the protective vaccine response. But blocking the protein restores vaccine efficacy in an animal model.

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes

December 5, 2024

The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and other blood diseases.

Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers

November 19, 2024

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.
Category navigation with Social links